BRAF and neoplasm: BRAF inhibitors (e.g., dabrafenib and vemurafenib) selectively occupy the ATP-binding pocket of BRAF-mutant monomers, thereby abrogating phosphorylation-dependent activation of the downstream MEK–ERK axis and suppressing tumor cell proliferation (6).